NeuClone
NeuClone
NeuClone is a clinical stage biopharmaceutical company exclusively developing and commercialising high quality biosimilar products. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at the scale and price to meet demand in both new and established markets globally. NeuClone is differentiated by our deep and unmatched pipeline, as well as our Right From the Start® approach where we continually confirm biosimilarity at the earliest stages and throughout development.
Videos
Images
Blog Posts
3rd June, 2019
AbbVie’s US Humira Monopoly: Four Years and $60 Billion of Additional Sales Protection
Introduction Approximately $60 billion in US Humira sales will remain uncontested over the next four...
4th March, 2019
Early Biosimilars Pave the Way for Recent Launches in Europe
Introduction With over a decade of real world biosimilar experience in Europe and now more...
8th January, 2019
Perjeta (Pertuzumab): Current Landscape and Biosimilar Potential
Introduction With the recent announcement that NeuClone is developing a biosimilar candidate of Perj...
11th October, 2018
On Your Marks: The Humira Biosimilar Race begins, but not in the U.S.
Introduction Five biosimilar copies of the world’s highest selling drug, Humira (adalimumab), are ab...
4th October, 2018
Key Themes Emerging from The FDA Biosimilar Public Hearing
Introduction With 27 speakers and 78 follow-up electronic submissions, the Food and Drug Administrat...
24th September, 2018
A Shift in Regulatory Thinking – Are Confirmatory Phase III Studies Redundant for Biosimilars?
In recent years biosimilar regulatory requirements across the world have converged and a broadly acc...
17th September, 2018
Introducing the NeuClone Biosimilar Brief
The NeuClone Biosimilar Brief is a biosimilar industry publication written by NeuClone exploring bio...